Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO5323441 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Part I | EXPERIMENTAL | - |
| Part II (A) | EXPERIMENTAL | - |
| Part II (B) | ACTIVE_COMPARATOR | - |
| Single Arm | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| RO5323441 | DRUG | escalating doses iv |
| sorafenib | DRUG | 400 mg orally twice daily to once every other day |
Inclusion Criteria: * Adult patients \>/= 21 years of age * Advanced or metastatic and/or unresectable hepatocellular carcinoma * At least 1 measurable lesion according to RECIST criteria * Primary tumor in situ (Expansion Cohort Part I, Part II) * Eastern Cooperative Oncology Group (ECOG) performa...
RO5323441 is an investigational small molecule being studied for use in oncology, specifically for hepatocellular carcinoma, glioblastoma multiforme, colorectal cancer, and ovarian cancer. It has been evaluated in Phase 1 clinical trials, both as a single agent and in combination with other therapies.
RO5323441 is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company has sponsored Phase 1 clinical trials of this investigational oncology drug.
RO5323441 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. All completed trials for this asset are Phase 1 studies.
RO5323441 has been studied in three completed Phase 1 trials: NCT01148758 in metastatic treatment-refractory colorectal or ovarian cancer, NCT01308684 in recurrent glioblastoma in combination with bevacizumab, and NCT01308723 in hepatocellular carcinoma in combination with sorafenib.
RO5323441 is an investigational small molecule developed by Roche. No alternative names for this drug have been reported in clinical trial records. It is distinct from the combination agents it has been studied with, such as bevacizumab and sorafenib.